Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial

Overview of attention for article published in Frontiers in oncology, August 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 22 Dimensions

Readers on

mendeley: 19 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 26,339 followers.

Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial: Background Neoadjuvant chemotherapies have been widely recommended #oncology… https://t.co/gmR

29 Aug 2022

Reply Repost Favourite

New research: Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial: Background Neoadjuvant chemotherapies have been widely recommended… https://t.c

27 Aug 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.